AN2 Therapeutics Announces Director Changes and Compensatory Arrangements
Ticker: ANTX · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1880438
Sentiment: neutral
Topics: director-change, compensation, corporate-governance
TL;DR
AN2 Therapeutics swapped a director, appointed a new one, and disclosed executive pay details.
AI Summary
On August 7, 2024, AN2 Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Jonathan Leff and the appointment of Dr. David Epstein as a new director. Additionally, AN2 Therapeutics disclosed compensatory arrangements for certain officers and reported on cost-associated exit or disposal activities.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence.
Risk Assessment
Risk Level: medium — Director departures and changes in compensatory arrangements can sometimes indicate underlying issues or strategic shifts within a company.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan Leff (person) — Departing Director
- Dr. David Epstein (person) — Appointed Director
- August 7, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from the Board of Directors at AN2 Therapeutics?
Dr. Jonathan Leff has departed from the Board of Directors.
Who has been appointed as a new director to the Board of AN2 Therapeutics?
Dr. David Epstein has been appointed as a new director.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated August 7, 2024.
What specific items are covered in this 8-K filing by AN2 Therapeutics?
The filing covers cost associated with exit or disposal activities, departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and other events.
What is the principal executive office address for AN2 Therapeutics?
The principal executive office is located at 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
Filing Stats: 943 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-08-08 16:50:01
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value ANTX The Nasdaq Global Se
- $2 — ncur aggregate charges of approximately $2-$3 million, including severance and oth
- $3 m — r aggregate charges of approximately $2-$3 million, including severance and other em
Filing Documents
- d865374d8k.htm (8-K) — 27KB
- d865374dex991.htm (EX-99.1) — 14KB
- 0001193125-24-197047.txt ( ) — 172KB
- antx-20240807.xsd (EX-101.SCH) — 3KB
- antx-20240807_lab.xml (EX-101.LAB) — 18KB
- antx-20240807_pre.xml (EX-101.PRE) — 11KB
- d865374d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AN2 Therapeutics, Inc. Date: August 8, 2024 By: /s/ Joshua Eizen Joshua Eizen Chief Legal Officer